Gemini Therapeutics (GMTX) Financials

$40.27 +1.54 (+3.98%)

As of 04/14/2025

Annual Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-41	-36	-47	-76	-109
Consolidated Net Income / (Loss)	-41	-36	-47	-76	-109
Net Income / (Loss) Continuing Operations	-41	-36	-47	-76	-109
Total Pre-Tax Income	-41	-36	-47	-76	-109
Total Operating Income	-34	-31	-47	-91	-130
Total Gross Profit	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	34	31	47	91	130
Selling, General & Admin Expense	5.87	5.76	14	22	33
Research & Development Expense	28	25	33	69	97
Total Other Income / (Expense), net	-6.80	-5.04	0.65	15	21
Interest Expense	6.83	-	-	-	0.57
Interest & Investment Income	0.04	0.01	0.71	15	21
Income Tax Expense	-	-	0.00	0.10	0.36
Other Gains / (Losses), net	-	-	-	-	-0.00
Basic Earnings per Share	($2.70)	($40.95)	($45.05)	($3.42)	($3.96)
Weighted Average Basic Shares Outstanding	15.12M	878.41K	1.04M	22.32M	27.61M
Diluted Earnings per Share	($2.70)	($40.95)	($45.05)	($3.42)	($3.96)
Weighted Average Diluted Shares Outstanding	15.12M	878.41K	1.04M	22.32M	27.61M
Weighted Average Basic & Diluted Shares Outstanding	15.12M	40.36M	19.00M	24.68M	34.57M

This table shows Gemini Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-16	-11	-23	-16	-14	-24	-27	-26	-27	-29
Consolidated Net Income / (Loss)	-16	-11	-23	-16	-14	-24	-27	-26	-27	-29
Net Income / (Loss) Continuing Operations	-16	-11	-23	-16	-14	-24	-27	-26	-27	-29
Total Pre-Tax Income	-16	-11	-23	-16	-14	-24	-27	-26	-26	-29
Total Operating Income	-10	-15	-25	-17	-19	-30	-31	-31	-33	-35
Total Operating Expenses	10	15	25	17	19	30	31	31	33	35
Selling, General & Admin Expense	2.59	5.01	4.95	5.23	4.54	7.15	7.76	7.37	8.17	9.75
Research & Development Expense	7.89	10	20	12	14	23	24	23	25	25
Total Other Income / (Expense), net	-5.67	3.78	2.37	1.41	4.86	6.17	4.52	4.56	6.37	5.27
Interest & Investment Income	0.27	0.39	2.37	2.91	4.84	4.68	4.52	4.57	6.36	5.84
Income Tax Expense	0.00	-	0.02	0.02	0.02	0.03	0.01	0.06	0.11	0.18
Basic Earnings per Share	($16.82)	($10.82)	($1.20)	($0.74)	($0.58)	($1.06)	($1.09)	($1.03)	($0.89)	($1.07)
Weighted Average Basic Shares Outstanding	960.32K	1.04M	18.95M	21.48M	24.32M	22.32M	24.81M	25.65M	29.94M	27.61M
Diluted Earnings per Share	($16.82)	($10.82)	($1.20)	($0.74)	($0.58)	($1.06)	($1.09)	($1.03)	($0.89)	($1.07)
Weighted Average Diluted Shares Outstanding	960.32K	1.04M	18.95M	21.48M	24.32M	22.32M	24.81M	25.65M	29.94M	27.61M
Basic & Diluted Earnings per Share	-	($10.82)	-	-	-	($1.06)	-	-	-	($1.07)
Weighted Average Basic & Diluted Shares Outstanding	43.33M	19.00M	19.80M	22.88M	24.14M	24.68M	24.72M	29.73M	29.76M	34.57M

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	0.45	62	107	166	-168
Net Cash From Operating Activities	-33	-28	-42	-73	-94
Net Cash From Continuing Operating Activities	-34	-28	-42	-73	-94
Net Income / (Loss) Continuing Operations	-41	-36	-47	-76	-109
Consolidated Net Income / (Loss)	-41	-36	-47	-76	-109
Depreciation Expense	0.32	0.03	0.09	0.10	0.16
Amortization Expense	-	-	-	0.00	-5.30
Non-Cash Adjustments To Reconcile Net Income	7.47	6.98	2.04	5.94	22
Changes in Operating Assets and Liabilities, net	-0.73	1.43	2.44	-3.07	-1.43
Net Cash From Investing Activities	-0.02	-0.07	-0.15	-0.09	-292
Net Cash From Continuing Investing Activities	-0.02	-0.07	-0.15	-0.09	-292
Purchase of Property, Plant & Equipment	-0.02	-0.07	-0.15	-0.09	-0.51
Purchase of Investments	-	-	-	0.00	-387
Sale and/or Maturity of Investments	-	-	-	0.00	95
Net Cash From Financing Activities	34	90	149	239	218
Net Cash From Continuing Financing Activities	34	90	149	239	218
Repayment of Debt	0.00	0.00	0.00	0.00	-1.39
Issuance of Debt	14	0.00	0.00	0.00	29
Issuance of Common Equity	20	0.00	54	199	188
Other Financing Activities, net	0.16	0.07	95	40	2.98
Cash Interest Paid	0.35	0.00	0.00	0.00	0.20
Cash Income Taxes Paid	-	0.00	0.00	0.11	0.30

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-9.69	139	42	141	-7.06	-10	-18	-62	-88	-0.20
Net Cash From Operating Activities	-9.69	-9.67	-35	-13	-7.48	-18	-34	-15	-17	-28
Net Cash From Continuing Operating Activities	-9.69	-9.67	-35	-13	-7.48	-18	-34	-15	-17	-28
Net Income / (Loss) Continuing Operations	-16	-11	-23	-16	-14	-24	-27	-26	-27	-29
Consolidated Net Income / (Loss)	-16	-11	-23	-16	-14	-24	-27	-26	-27	-29
Depreciation Expense	0.02	0.03	0.03	0.03	0.03	0.03	0.03	0.11	0.01	0.01
Amortization Expense	-	-	-	-	-	-	-	-	-2.50	-2.21
Non-Cash Adjustments To Reconcile Net Income	6.22	-2.39	1.03	2.60	1.70	0.61	4.13	12	10	-4.72
Changes in Operating Assets and Liabilities, net	0.22	3.94	-14	0.60	4.92	5.15	-11	-0.97	1.54	8.80
Net Cash From Investing Activities	-0.02	-0.01	-0.03	-0.01	-0.05	-0.00	-0.07	-220	-71	-1.43
Net Cash From Continuing Investing Activities	-0.02	-0.01	-0.03	-0.01	-0.05	-0.00	-0.07	-220	-71	-1.43
Purchase of Property, Plant & Equipment	-0.02	-0.01	-0.03	-0.01	-0.05	-0.00	-0.07	0.00	0.01	-0.45
Purchase of Investments	-	-	-	-	-	-	-	-	-94	-73
Sale and/or Maturity of Investments	-	-	-	-	-	-	-	-	-	72
Net Cash From Financing Activities	0.02	149	77	154	0.46	7.76	16	173	0.43	29
Net Cash From Continuing Financing Activities	0.02	149	77	154	0.46	7.76	16	173	0.43	29
Other Financing Activities, net	0.02	95	28	-27	0.62	38	0.81	0.57	0.40	1.20
Cash Income Taxes Paid	-	-	0.00	-	0.08	0.03	0.00	0.03	0.00	0.26

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Total Assets	8.32	92	200	368	497
Total Current Assets	5.07	90	198	366	494
Cash & Equivalents	4.50	88	195	360	192
Short-Term Investments	-	-	-	0.00	297
Prepaid Expenses	0.56	2.45	3.88	5.28	3.73
Plant, Property, & Equipment, net	0.29	0.11	0.17	0.17	0.75
Total Noncurrent Assets	2.96	1.82	1.55	2.16	2.41
Other Noncurrent Operating Assets	2.96	1.82	1.55	2.16	2.41
Total Liabilities & Shareholders' Equity	8.32	92	200	368	497
Total Liabilities	30	15	24	23	53
Total Current Liabilities	25	13	23	21	23
Accounts Payable	2.38	2.56	16	13	7.95
Accrued Expenses	5.81	4.10	6.11	8.15	15
Other Current Liabilities	-	6.77	0.31	0.67	0.13
Total Noncurrent Liabilities	5.30	1.33	1.03	1.44	30
Long-Term Debt	4.95	-	-	0.00	28
Other Noncurrent Operating Liabilities	0.35	1.33	1.03	1.44	1.55
Commitments & Contingencies	-	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-22	78	177	345	444
Total Preferred & Common Equity	-22	-64	177	345	444
Preferred Stock	0.00	142	-	0.00	0.00
Total Common Equity	-22	-64	177	345	444
Common Stock	91	1.19	289	534	741
Retained Earnings	-113	-65	-112	-189	-298
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	0.29

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	106	244	384	376	354	510	495
Total Current Assets	105	242	382	374	352	508	493
Cash & Equivalents	102	236	378	371	343	281	193
Short-Term Investments	-	-	-	-	-	220	295
Prepaid Expenses	2.93	5.72	4.13	3.72	9.33	7.30	5.79
Plant, Property, & Equipment, net	0.00	0.18	0.16	0.18	0.21	0.10	0.08
Total Noncurrent Assets	1.37	1.46	2.28	2.05	2.02	1.88	1.91
Other Noncurrent Operating Assets	1.37	1.46	2.28	2.05	2.02	1.88	1.91
Total Liabilities & Shareholders' Equity	106	244	384	376	354	510	495
Total Liabilities	1.46	11	13	18	16	21	27
Total Current Liabilities	1.46	9.98	9.68	14	15	20	25
Accounts Payable	1.14	5.64	5.21	8.50	5.27	4.75	3.55
Accrued Expenses	0.33	4.03	4.15	5.57	8.82	15	22
Other Current Liabilities	-	0.31	0.32	0.35	0.77	0.76	0.08
Total Noncurrent Liabilities	0.00	0.95	3.27	3.11	1.26	1.08	1.71
Other Noncurrent Operating Liabilities	0.00	0.95	3.27	3.11	1.26	1.08	1.71
Commitments & Contingencies	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	105	233	371	359	338	489	468
Total Preferred & Common Equity	105	233	371	359	338	489	468
Total Common Equity	105	233	371	359	338	489	468
Common Stock	315	368	522	524	554	731	736
Retained Earnings	-210	-135	-151	-165	-216	-242	-269
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-0.06	0.74

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-6.60%	-31.98%	-91.85%	-48.16%
EBIT Growth	0.00%	-5.68%	-32.11%	-91.70%	-42.35%
NOPAT Growth	0.00%	9.13%	-53.48%	-91.94%	-42.35%
Net Income Growth	0.00%	11.92%	-30.19%	-63.22%	-43.08%
EPS Growth	0.00%	11.92%	-10.01%	92.41%	-15.79%
Operating Cash Flow Growth	0.00%	15.82%	-53.45%	-73.87%	-27.86%
Free Cash Flow Firm Growth	0.00%	0.00%	-60.09%	-159.87%	-32.40%
Invested Capital Growth	0.00%	-119.79%	-73.47%	15.27%	-17.76%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	40.87%	-129.18%	-22.29%	-9.45%
EBIT Q/Q Growth	0.00%	41.08%	-130.60%	-22.26%	-5.12%
NOPAT Q/Q Growth	0.00%	49.34%	-291.48%	-19.22%	-3.87%
Net Income Q/Q Growth	0.00%	47.38%	-167.49%	-19.25%	-5.68%
EPS Q/Q Growth	0.00%	47.38%	-147.12%	-29.55%	-14.45%
Operating Cash Flow Q/Q Growth	0.00%	50.73%	-222.81%	-12.45%	-11.62%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-84.47%	-70.15%	-10.69%
Invested Capital Q/Q Growth	0.00%	-305.43%	-736.43%	-31.94%	7.38%
Profitability Metrics	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.13%	100.33%
Interest Burden Percent	119.94%	99.96%	98.51%	83.76%	84.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	186.80%	-128.94%	-36.84%	-29.30%	-27.73%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	186.80%	198.90%	-16.28%	-29.30%	-27.73%
Return on Equity Simple (ROE_SIMPLE)	186.80%	56.02%	-26.52%	-22.15%	-24.65%
Net Operating Profit after Tax (NOPAT)	-24	-22	-33	-64	-91
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	99.25%	-40.38%	-9.62%	-4.56%	-4.51%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-18.48%	-19.24%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-34	-36	-48	-91	-130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-34	-36	-47	-91	-135
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.16	4.04	4.25
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.16	4.04	4.25
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	-0.99	0.00	0.00	0.00	0.06
Long-Term Debt to Equity	-0.23	0.00	0.00	0.00	0.06
Financial Leverage	-0.78	-1.27	-1.11	-1.06	-1.04
Leverage Ratio	-0.38	1.81	1.15	1.09	1.10
Compound Leverage Factor	-0.46	1.80	1.13	0.91	0.92
Debt to Total Capital	-9,791.86%	0.00%	0.00%	0.00%	6.00%
Short-Term Debt to Total Capital	-7,551.58%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-2,240.27%	0.00%	0.00%	0.00%	6.00%
Preferred Equity to Total Capital	0.00%	182.68%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	9,891.86%	-82.68%	100.00%	100.00%	94.00%
Debt to EBITDA	-0.64	0.00	0.00	0.00	-0.21
Net Debt to EBITDA	-0.51	0.00	0.00	0.00	3.42
Long-Term Debt to EBITDA	-0.15	0.00	0.00	0.00	-0.21
Debt to NOPAT	-0.91	0.00	0.00	0.00	-0.31
Net Debt to NOPAT	-0.72	0.00	0.00	0.00	5.08
Long-Term Debt to NOPAT	-0.21	0.00	0.00	0.00	-0.31
Altman Z-Score	-31.95	3.83	0.22	36.16	20.72
Noncontrolling Interest Sharing Ratio	0.00%	254.26%	55.79%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.20	6.74	8.79	17.06	21.17
Quick Ratio	0.18	6.56	8.62	16.81	21.01
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-16	-26	-67	-88
Operating Cash Flow to CapEx	-148,672.73%	-40,491.18%	-27,981.46%	-82,541.57%	-18,599.21%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-154.01
Operating Cash Flow to Interest Expense	-4.79	0.00	0.00	0.00	-164.21
Operating Cash Flow Less CapEx to Interest Expense	-4.79	0.00	0.00	0.00	-165.09
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	-4.72	-10	-18	-15	-18
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-5.66	-7.63	2.75	-2.71
Enterprise Value (EV)	188	179	-166	1,034	1,425
Market Capitalization	171	125	29	1,394	1,887
Book Value per Share	($1.41)	($1.49)	$4.08	$14.30	$14.91
Tangible Book Value per Share	($1.41)	($1.49)	$4.08	$14.30	$14.91
Total Capital	-0.22	78	177	345	472
Total Debt	22	0.00	0.00	0.00	28
Total Long-Term Debt	4.95	0.00	0.00	0.00	28
Net Debt	17	-88	-195	-360	-462
Capital Expenditures (CapEx)	0.02	0.07	0.15	0.09	0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.63	-11	-19	-16	-20
Debt-free Net Working Capital (DFNWC)	-3.12	77	176	344	470
Net Working Capital (NWC)	-20	77	176	344	470
Net Nonoperating Expense (NNE)	17	14	14	13	19
Net Nonoperating Obligations (NNO)	17	-88	-195	-360	-462
Total Depreciation and Amortization (D&A)	0.32	0.03	0.09	0.10	-5.15
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($53.40)	($45.05)	($3.42)	($3.96)
Adjusted Weighted Average Basic Shares Outstanding	0.00	1.44M	1.04M	22.32M	27.61M
Adjusted Diluted Earnings per Share	$0.00	($53.40)	($45.05)	($3.42)	($3.96)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	1.44M	1.04M	22.32M	27.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	($53.40)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	1.35M	19.00M	24.68M	34.57M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-22	-33	-64	-91
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-4.99	0.00	0.00	0.00	-226.78
NOPAT to Interest Expense	-3.49	0.00	0.00	0.00	-158.75
EBIT Less CapEx to Interest Expense	-4.99	0.00	0.00	0.00	-227.67
NOPAT Less CapEx to Interest Expense	-3.49	0.00	0.00	0.00	-159.63
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	10.87%	-176.68%	-155.03%	-95.86%	-15.40%	-142.95%	-25.25%	-63.52%	-86.74%	-30.33%
EBIT Growth	11.02%	-176.08%	-154.82%	-95.67%	-15.38%	-142.64%	-25.23%	-63.89%	-73.38%	-22.41%
NOPAT Growth	43.20%	-151.73%	-152.26%	-44.22%	-80.91%	-97.82%	-25.22%	-78.05%	-73.31%	-16.28%
Net Income Growth	12.94%	-162.20%	-131.21%	-66.46%	12.56%	-109.70%	-18.30%	-65.25%	-88.35%	-24.93%
EPS Growth	12.94%	-152.58%	88.75%	92.70%	96.55%	90.20%	9.17%	-39.19%	-53.45%	-0.94%
Operating Cash Flow Growth	39.79%	-149.57%	-158.86%	-38.39%	22.86%	-84.13%	5.26%	-20.98%	-132.22%	-54.94%
Free Cash Flow Firm Growth	-112.03%	-111.11%	-119.07%	59.93%	108.85%	-715.80%	-19.33%	-245.19%	-1,446.16%	8.81%
Invested Capital Growth	210.50%	-73.47%	1.38%	-654.56%	-508.73%	15.27%	-27.39%	-89.82%	-67.74%	-17.76%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-70.73%	29.20%	-116.25%	25.07%	-0.60%	-49.04%	-11.48%	2.17%	-14.88%	-4.02%
EBIT Q/Q Growth	-70.59%	29.16%	-116.00%	25.04%	-0.59%	-48.98%	-11.48%	1.90%	-6.42%	-5.18%
NOPAT Q/Q Growth	12.78%	-43.34%	-67.27%	31.03%	-9.41%	-56.74%	-5.88%	1.94%	-6.50%	-5.16%
Net Income Q/Q Growth	-68.58%	30.38%	-102.61%	30.00%	11.44%	-66.97%	-14.29%	2.22%	-0.94%	-10.74%
EPS Q/Q Growth	-68.58%	35.67%	88.91%	38.33%	21.62%	-82.76%	-2.83%	5.50%	13.59%	-20.22%
Operating Cash Flow Q/Q Growth	-5.42%	0.28%	-266.95%	64.12%	41.24%	-138.04%	-88.80%	54.19%	-12.79%	-58.82%
Free Cash Flow Firm Q/Q Growth	-10.98%	77.32%	-510.99%	73.94%	124.51%	-2,190.71%	10.63%	24.63%	4.41%	-41.62%
Invested Capital Q/Q Growth	145.87%	-736.43%	80.20%	-78.95%	-81.22%	-31.94%	70.22%	-166.64%	-60.14%	7.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.10%	100.15%	100.14%	100.14%	100.02%	100.23%	100.43%	100.60%
Interest Burden Percent	98.36%	96.66%	90.58%	84.55%	74.44%	83.43%	85.64%	85.18%	80.63%	84.75%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-14.27%	-36.84%	-34.69%	-27.66%	-27.65%	-29.30%	-28.23%	-21.16%	-25.03%	-27.73%
Cash Return on Invested Capital (CROIC)	-490.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-14.27%	-16.28%	-34.69%	-27.66%	-27.65%	-29.30%	-28.23%	-21.16%	-25.03%	-27.73%
Return on Equity Simple (ROE_SIMPLE)	-16.74%	0.00%	-25.66%	-17.81%	-17.85%	0.00%	-23.84%	-18.62%	-22.11%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.34	-11	-18	-12	-13	-21	-22	-22	-23	-24
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-7.19%	-0.52%	-2.95%	-1.58%	-0.36%	-1.00%	-1.70%	-1.08%	-0.84%	-1.28%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-6.03%	-	-	-	-5.12%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-16	-12	-25	-19	-19	-28	-31	-31	-33	-35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-12	-25	-19	-19	-28	-31	-31	-35	-37
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.68	0.16	1.73	2.37	2.99	4.04	4.55	2.28	3.12	4.25
Price to Tangible Book Value (P/TBV)	0.68	0.16	1.73	2.37	2.99	4.04	4.55	2.28	3.12	4.25
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06
Financial Leverage	-1.00	-1.11	-1.02	-1.01	-1.02	-1.06	-1.01	-1.02	-1.04	-1.04
Leverage Ratio	1.07	1.15	1.07	1.04	1.04	1.09	1.05	1.04	1.05	1.10
Compound Leverage Factor	1.05	1.11	0.97	0.88	0.77	0.91	0.90	0.89	0.85	0.93
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	94.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.21
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.42
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.21
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.31
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.08
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.31
Altman Z-Score	26.95	0.81	22.14	41.16	37.17	36.72	57.22	31.54	32.39	21.35
Noncontrolling Interest Sharing Ratio	0.00%	55.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	71.49	8.79	24.26	39.42	25.96	17.06	23.70	25.02	19.36	21.17
Quick Ratio	69.49	8.62	23.69	39.00	25.70	16.81	23.07	24.66	19.13	21.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-13	-2.89	-18	-4.60	1.13	-24	-21	-16	-15	-21
Operating Cash Flow to CapEx	-51,010.53%	-80,541.67%	-122,296.55%	-106,033.33%	-16,613.33%	-593,200.00%	-50,147.76%	0.00%	0.00%	-6,140.98%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2.83	-18	-3.57	-6.38	-12	-15	-4.54	-12	-19	-18
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	5.39	-7.63	0.05	-7.53	-14	2.75	-0.98	-5.73	-7.84	-2.71
Enterprise Value (EV)	-31	-166	166	501	704	1,034	1,194	613	973	1,425
Market Capitalization	71	29	403	879	1,075	1,394	1,537	1,114	1,461	1,887
Book Value per Share	$2.42	$4.08	$5.37	$18.75	$15.69	$14.30	$13.70	$19.77	$15.74	$14.91
Tangible Book Value per Share	$2.42	$4.08	$5.37	$18.75	$15.69	$14.30	$13.70	$19.77	$15.74	$14.91
Total Capital	105	177	233	371	359	345	338	489	468	472
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	28
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	28
Net Debt	-102	-195	-236	-378	-371	-360	-343	-501	-487	-462
Capital Expenditures (CapEx)	0.02	0.01	0.03	0.01	0.05	0.00	0.07	-0.00	-0.01	0.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.46	-19	-4.26	-5.55	-11	-16	-5.52	-13	-20	-20
Debt-free Net Working Capital (DFNWC)	103	176	232	372	360	344	337	488	468	470
Net Working Capital (NWC)	103	176	232	372	360	344	337	488	468	470
Net Nonoperating Expense (NNE)	8.81	0.73	5.19	3.82	0.85	2.78	4.93	4.76	3.60	5.27
Net Nonoperating Obligations (NNO)	-102	-195	-236	-378	-371	-360	-343	-501	-487	-462
Total Depreciation and Amortization (D&A)	0.02	0.03	0.03	0.03	0.03	0.03	0.03	0.11	-2.49	-2.20
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.40)	($10.82)	($1.20)	($0.74)	($0.58)	($1.06)	($1.09)	($1.03)	($0.89)	($1.07)
Adjusted Weighted Average Basic Shares Outstanding	1.44M	1.04M	18.95M	21.48M	24.32M	22.32M	24.81M	25.65M	29.94M	27.61M
Adjusted Diluted Earnings per Share	($2.40)	($10.82)	($1.20)	($0.74)	($0.58)	($1.06)	($1.09)	($1.03)	($0.89)	($1.07)
Adjusted Weighted Average Diluted Shares Outstanding	1.44M	1.04M	18.95M	21.48M	24.32M	22.32M	24.81M	25.65M	29.94M	27.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	($10.82)	$0.00	$0.00	$0.00	($1.06)	$0.00	$0.00	$0.00	($1.07)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.44M	19.00M	19.80M	22.88M	24.14M	24.68M	24.72M	29.73M	29.76M	34.57M
Normalized Net Operating Profit after Tax (NOPAT)	-7.34	-11	-18	-12	-13	-21	-22	-22	-23	-24
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Gemini Therapeutics' Financials

When does Gemini Therapeutics's financial year end?

According to the most recent income statement we have on file, Gemini Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Gemini Therapeutics' net income changed over the last 4 years?

Gemini Therapeutics' net income appears to be on an upward trend, with a most recent value of -$109.36 million in 2024, rising from -$40.84 million in 2020. The previous period was -$76.43 million in 2023.

What is Gemini Therapeutics's operating income?

Gemini Therapeutics's total operating income in 2024 was -$129.72 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $129.72 million

How has Gemini Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Gemini Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Gemini Therapeutics have?

Gemini Therapeutics' total liabilities were at $53.19 million at the end of 2024, a 132.5% increase from 2023, and a 76.2% increase since 2020.

How much cash does Gemini Therapeutics have?

In the past 4 years, Gemini Therapeutics' cash and equivalents has ranged from $4.50 million in 2020 to $360.38 million in 2023, and is currently $192.43 million as of their latest financial filing in 2024.

How has Gemini Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Gemini Therapeutics' book value per share changed from -1.41 in 2020 to 14.91 in 2024, a change of -1,159.3%.

Remove Ads

Related Companies

This page (NASDAQ:GMTX) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Financials

Frequently Asked Questions About Gemini Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Financials

Annual Income Statements for Gemini Therapeutics

Quarterly Income Statements for Gemini Therapeutics

Annual Cash Flow Statements for Gemini Therapeutics

Quarterly Cash Flow Statements for Gemini Therapeutics

Annual Balance Sheets for Gemini Therapeutics

Quarterly Balance Sheets for Gemini Therapeutics

Annual Metrics and Ratios for Gemini Therapeutics

Quarterly Metrics and Ratios for Gemini Therapeutics

Frequently Asked Questions About Gemini Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools